Our current study suggests that the suppression of HSP90AB1 by ME enhances the sensitivity of ovarian cancer cells to cisplatin, suggesting that inhibition of HSP90AB1 by ME contributes to DNA damage and apoptosis in ovarian cancer cells. Here, HSP90AB1 is linked to ovarian cancer.